Thermo Fisher Scientific launches new immuno-oncology collaboration programme

Thermo Fisher Scientific has announced the launch of its new Center of Excellence in Immunotherapy programme.

The scheme is designed to foster strategic collaborations with institutions around the globe to accelerate research and clinical trials in immuno-oncology, with Washington University School of Medicine named as the first partner organisation.

Under the new programme, the university will adopt a company-centric workflow for immuno-oncology research, ranging from novel whole transcriptome technologies to single-cell assays.

Dr. Robert Schreiber, a professor at Washington University School of Medicine, will lead research to develop individualised therapeutic cancer vaccines, employing genomic and bioinformatic approaches to identify mutations within tumours that form tumour-specific neoantigens.

Additionally, the team will work to produce vaccines that neoantigens unique to a variety of cancer types and to each patient, creating a personalised method of addressing the disease.

Alex Forrest-Hay, director of business development for Thermo Fisher Scientific, said: "We believe that establishing strategic partnerships with world-leading research laboratories is essential to accelerating biomarker development and to the future success of the next generation of immunotherapies."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.